Inovio Pharmaceuticals (NASDAQ:INO) Raised to “Strong-Buy” at Zacks Research

Inovio Pharmaceuticals (NASDAQ:INO) was upgraded by equities research analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research note issued on Wednesday,Zacks.com reports.

Several other brokerages have also recently commented on INO. Wall Street Zen cut shares of Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday, June 21st. HC Wainwright reaffirmed a “neutral” rating on shares of Inovio Pharmaceuticals in a research note on Thursday. Weiss Ratings raised shares of Inovio Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 29th. Piper Sandler reiterated an “overweight” rating and set a $4.00 target price on shares of Inovio Pharmaceuticals in a research report on Monday, August 3rd. Finally, Jefferies Financial Group raised Inovio Pharmaceuticals from a “hold” rating to a “positive” rating and increased their price target for the company from $1.80 to $3.00 in a research note on Thursday. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $3.17.

Inovio Pharmaceuticals Stock Up 16.9%

Inovio Pharmaceuticals stock opened at $0.90 on Wednesday. The business’s 50-day simple moving average is $1.03 and its 200 day simple moving average is $1.30. The stock has a market cap of $74.05 million, a price-to-earnings ratio of -0.99 and a beta of 1.52. Inovio Pharmaceuticals has a 12-month low of $0.56 and a 12-month high of $2.98.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings data on Wednesday, August 12th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.15. As a group, sell-side analysts expect that Inovio Pharmaceuticals will post -0.99 EPS for the current year.

Institutional Trading of Inovio Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Inovio Pharmaceuticals by 39.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company’s stock valued at $34,000 after acquiring an additional 5,894 shares during the period. Focus Partners Wealth acquired a new position in Inovio Pharmaceuticals during the third quarter valued at approximately $33,000. Raymond James Financial Inc. grew its holdings in Inovio Pharmaceuticals by 4,396.0% during the third quarter. Raymond James Financial Inc. now owns 16,680 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 16,309 shares during the period. GSA Capital Partners LLP increased its stake in Inovio Pharmaceuticals by 3.8% in the fourth quarter. GSA Capital Partners LLP now owns 459,828 shares of the biopharmaceutical company’s stock valued at $800,000 after purchasing an additional 16,724 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. bought a new stake in Inovio Pharmaceuticals in the third quarter valued at approximately $41,000. 26.79% of the stock is owned by institutional investors.

Trending Headlines about Inovio Pharmaceuticals

Here are the key news stories impacting Inovio Pharmaceuticals this week:

• Positive Sentiment: INO-3107 regulatory progress: The FDA’s review of Inovio’s biologics license application for recurrent respiratory papillomatosis is advancing toward an October 30, 2026 PDUFA decision date. The company is also preparing commercially for a potential launch, an important catalyst for the development-stage biotech. INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights
• Positive Sentiment: Smaller-than-expected loss: Inovio reported a second-quarter loss of $0.07 per share, substantially better than the $0.22 loss analysts expected. The narrower loss supports the near-term investment case, although the company remains unprofitable. Inovio Second-Quarter Earnings Results
• Positive Sentiment: Improved funding visibility: Management said its cash, cash equivalents, and short-term investments are expected to fund operations through late first quarter 2027, potentially covering the period through an INO-3107 launch if approved and reducing immediate financing pressure. Inovio Q2 2026 Earnings Call Highlights
• Positive Sentiment: Pipeline developments: Partner ApolloBio reported positive topline Phase 3 results for VGX-3100 in cervical dysplasia, while Inovio also highlighted progress in its DNA-encoded antibody and protein programs. Inovio Second-Quarter 2026 Financial Results
• Negative Sentiment: Key risks remain: INO-3107 still requires FDA approval, and the company continues to report losses. Any regulatory delay, rejection, weaker launch prospects, or future need for additional capital could pressure INO. Inovio Q2 2026 Earnings Call Transcript

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.